RE
SAGE

RBC Europe’s Sage Therapeutics SAGE Stock Holding History

RBC Europe’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-150
Closed -$21K – 1065
2019
Q3 		$21K Hold
150
– – ﹤0.01% 627
2019
Q2 		$27.5K Hold
150
– – ﹤0.01% 591
2019
Q1 		$23.9K Hold
150
– – ﹤0.01% 617
2018
Q4 		$14.4K Sell
150
-45
-23% -$5.15K ﹤0.01% 707
2018
Q3 		$27.5K Buy
+195
New +$30.1K ﹤0.01% 614

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

RBC Europe's SAGE Position: Q4 2019 in Review

RBC Europe sold out of Sage Therapeutics (SAGE) in Q4 2019, closing a stake of 150 shares — an estimated $21K sold.

RBC Europe first reported a position in SAGE in Q3 2018 and held it in 5 quarters. The position peaked at $27.5K in Q3 2018. 266 funds tracked by Wall St. Rank hold SAGE as of Q4 2019.

  • RBC Europe reported no remaining Sage Therapeutics position as of Q4 2019 after selling out during the quarter.
  • RBC Europe sold 150 Sage Therapeutics shares in Q4 2019, an estimated $21K.
  • RBC Europe first reported a position in Sage Therapeutics in Q3 2018 and held it in 5 quarters.
  • RBC Europe's Sage Therapeutics position peaked at $27.5K in Q3 2018.
  • 266 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2019.

Based on RBC Europe's 13F filing for Q4 2019, filed 9 Nov 2023.